Engineering <i>Escherichia coli</i>-Derived Nanoparticles for Vaccine Development
The development of effective vaccines necessitates a delicate balance between maximizing immunogenicity and minimizing safety concerns. Subunit vaccines, while generally considered safe, often fail to elicit robust and durable immune responses. Nanotechnology presents a promising approach to address...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/11/1287 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846152270028210176 |
|---|---|
| author | Shubing Tang Chen Zhao Xianchao Zhu |
| author_facet | Shubing Tang Chen Zhao Xianchao Zhu |
| author_sort | Shubing Tang |
| collection | DOAJ |
| description | The development of effective vaccines necessitates a delicate balance between maximizing immunogenicity and minimizing safety concerns. Subunit vaccines, while generally considered safe, often fail to elicit robust and durable immune responses. Nanotechnology presents a promising approach to address this dilemma, enabling subunit antigens to mimic critical aspects of native pathogens, such as nanoscale dimensions, geometry, and highly repetitive antigen display. Various expression systems, including <i>Escherichia coli</i> (<i>E. coli</i>), yeast, baculovirus/insect cells, and Chinese hamster ovary (CHO) cells, have been explored for the production of nanoparticle vaccines. Among these, <i>E. coli</i> stands out due to its cost-effectiveness, scalability, rapid production cycle, and high yields. However, the <i>E. coli</i> manufacturing platform faces challenges related to its unfavorable redox environment for disulfide bond formation, lack of post-translational modifications, and difficulties in achieving proper protein folding. This review focuses on molecular and protein engineering strategies to enhance protein solubility in <i>E. coli</i> and facilitate the in vitro reassembly of virus-like particles (VLPs). We also discuss approaches for antigen display on nanocarrier surfaces and methods to stabilize these carriers. These bioengineering approaches, in combination with advanced nanocarrier design, hold significant potential for developing highly effective and affordable <i>E. coli</i>-derived nanovaccines, paving the way for improved protection against a wide range of infectious diseases. |
| format | Article |
| id | doaj-art-6e27b70c6c4b4092a1d5348a8608b93a |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-6e27b70c6c4b4092a1d5348a8608b93a2024-11-26T18:24:44ZengMDPI AGVaccines2076-393X2024-11-011211128710.3390/vaccines12111287Engineering <i>Escherichia coli</i>-Derived Nanoparticles for Vaccine DevelopmentShubing Tang0Chen Zhao1Xianchao Zhu2Shanghai Reinovax Biologics Co., Ltd., Pudong New District, Shanghai 200135, ChinaShanghai Public Health Clinical Center, Fudan University, Shanghai 201058, ChinaShanghai Reinovax Biologics Co., Ltd., Pudong New District, Shanghai 200135, ChinaThe development of effective vaccines necessitates a delicate balance between maximizing immunogenicity and minimizing safety concerns. Subunit vaccines, while generally considered safe, often fail to elicit robust and durable immune responses. Nanotechnology presents a promising approach to address this dilemma, enabling subunit antigens to mimic critical aspects of native pathogens, such as nanoscale dimensions, geometry, and highly repetitive antigen display. Various expression systems, including <i>Escherichia coli</i> (<i>E. coli</i>), yeast, baculovirus/insect cells, and Chinese hamster ovary (CHO) cells, have been explored for the production of nanoparticle vaccines. Among these, <i>E. coli</i> stands out due to its cost-effectiveness, scalability, rapid production cycle, and high yields. However, the <i>E. coli</i> manufacturing platform faces challenges related to its unfavorable redox environment for disulfide bond formation, lack of post-translational modifications, and difficulties in achieving proper protein folding. This review focuses on molecular and protein engineering strategies to enhance protein solubility in <i>E. coli</i> and facilitate the in vitro reassembly of virus-like particles (VLPs). We also discuss approaches for antigen display on nanocarrier surfaces and methods to stabilize these carriers. These bioengineering approaches, in combination with advanced nanocarrier design, hold significant potential for developing highly effective and affordable <i>E. coli</i>-derived nanovaccines, paving the way for improved protection against a wide range of infectious diseases.https://www.mdpi.com/2076-393X/12/11/1287subunit vaccinesmolecular and protein engineeringreassemblyvirus-like particles<i>E. coli</i>-derived nanovaccines |
| spellingShingle | Shubing Tang Chen Zhao Xianchao Zhu Engineering <i>Escherichia coli</i>-Derived Nanoparticles for Vaccine Development Vaccines subunit vaccines molecular and protein engineering reassembly virus-like particles <i>E. coli</i>-derived nanovaccines |
| title | Engineering <i>Escherichia coli</i>-Derived Nanoparticles for Vaccine Development |
| title_full | Engineering <i>Escherichia coli</i>-Derived Nanoparticles for Vaccine Development |
| title_fullStr | Engineering <i>Escherichia coli</i>-Derived Nanoparticles for Vaccine Development |
| title_full_unstemmed | Engineering <i>Escherichia coli</i>-Derived Nanoparticles for Vaccine Development |
| title_short | Engineering <i>Escherichia coli</i>-Derived Nanoparticles for Vaccine Development |
| title_sort | engineering i escherichia coli i derived nanoparticles for vaccine development |
| topic | subunit vaccines molecular and protein engineering reassembly virus-like particles <i>E. coli</i>-derived nanovaccines |
| url | https://www.mdpi.com/2076-393X/12/11/1287 |
| work_keys_str_mv | AT shubingtang engineeringiescherichiacoliiderivednanoparticlesforvaccinedevelopment AT chenzhao engineeringiescherichiacoliiderivednanoparticlesforvaccinedevelopment AT xianchaozhu engineeringiescherichiacoliiderivednanoparticlesforvaccinedevelopment |